Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 29, 2024Anticancer Research

A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMariko NishiokaNONaohiro OkanoMWMasashi Wakabayashi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nishioka et al. (2024) studied this question.

synapsesocial.com/papers/68e76e44b6db6435876e36a4https://doi.org/10.21873/anticanres.16919
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer2021 · 12 citations
  2. 2Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis2026
  3. 3Impact of response to gemcitabine-based neoadjuvant therapy on the outcomes of gemcitabine plus nab-paclitaxel after recurrence in pancreatic cancer.2026
  4. 4Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit2026
  5. 5Real-world evidence of the efficacy and safety of first-line chemotherapy gemcitabine and nab-paclitaxel for elderly patients with metastatic pancreatic cancer2026